GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Accumulated other comprehensive income (loss)

Can Fite Biofarma (Can Fite Biofarma) Accumulated other comprehensive income (loss) : $1.13 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Can Fite Biofarma's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $1.13 Mil.

Can Fite Biofarma's quarterly Accumulated other comprehensive income (loss) stayed the same from Jun. 2023 ($1.13 Mil) to Sep. 2023 ($1.13 Mil) and stayed the same from Sep. 2023 ($1.13 Mil) to Dec. 2023 ($1.13 Mil).

Can Fite Biofarma's annual Accumulated other comprehensive income (loss) stayed the same from Dec. 2021 ($1.13 Mil) to Dec. 2022 ($1.13 Mil) and stayed the same from Dec. 2022 ($1.13 Mil) to Dec. 2023 ($1.13 Mil).


Can Fite Biofarma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Can Fite Biofarma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Accumulated other comprehensive income (loss) Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.13 1.13 1.13 1.13

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 1.13 1.13 1.13 1.13

Can Fite Biofarma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


Can Fite Biofarma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019